SBDM 07
Alternative Names: SBDM-07Latest Information Update: 21 Aug 2024
At a glance
- Originator Shilpa Biologicals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Ovarian hyperstimulation syndrome
Highest Development Phases
- Research Ovarian hyperstimulation syndrome
Most Recent Events
- 05 Aug 2024 SBDM 07 is available for licensing as of 05 Aug 2024. https://www.shilpabio.com/partnerships/
- 05 Aug 2024 Early research in Ovarian-hyperstimulation-syndrome in India (Parenteral), prior to August 2024 (Shilpa Biologicals pipeline, December 2024)